Aptima® Herpes Simplex Viruses (HSV) 1 & 2 Test
1 in 6 Americans between the ages of 14-49 have genital herpes1
The causative factors for this, HSV-1 and HSV-2, are very prevalent. Nearly 70% of the global population is impacted by HSV-1, while prevalence for HSV-2 in the United States alone is estimated at over 24 million.1,2,3 While these viruses may be indistinguishable on initial clinical representation, they may present different health implications.
Estimated prevalence of STIs in the United States (2013)2
Empower your patients with a type-specific treatment plan
Each HSV type requires a unique treatment. Some cases of HSV-1 are asymptomatic.4 HSV-2 is likely to have a greater risk of transmission, and is associated with higher risk of HIV co-infection.4 Thus, treatment plans should include HIV testing and HIV reduction strategies.
Determine the appropriate treatment regimen of antiviral medication4
Providers can counsel patients according to infection type and prevent sexual and perinatal transmission4
Patients can prevent transmission to neonates and among sex partners5
NAAT tests are guideline-recommended for diagnosis of HSV infection with symptoms
WHO Recommendation5
CDC Recommendation4
ACOG Recommendation6
The Aptima HSV 1 & 2 assay:
Proven performance in sensitivity and specificity7
| HSV–1 | HSV–2 | |||
|---|---|---|---|---|
| Sample Type | Sensitivity | Specificity | Sensitivity | Specificity |
| Aptima Multitest Swab | 94.7% | 99.6% | 98.4% | 92.8% |
| Viral Transport Medium | 93.4% | 99.8% | 96.9% | 97.5% |